Cargando…

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

BACKGROUND: Inhibiting catechol‐O‐methyltransferase extends the plasma half‐life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations. OBJECTIVES: To evaluate the effects of once‐daily opicapone o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Moreira, Joana, Guimarães, Bruno, Rocha, José‐Francisco, Soares‐da‐Silva, Patrício
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804871/ https://www.ncbi.nlm.nih.gov/pubmed/36054562 http://dx.doi.org/10.1002/mds.29193

Ejemplares similares

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions
por: Ferreira, J. J., et al.
Publicado: (2019)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease
por: Jost, Wolfgang H
Publicado: (2022)

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Kwak, Nayoung, et al.
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
por: Annus, Ádám, et al.
Publicado: (2017)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Poewe, Werner, et al.
Publicado: (2010)

Opicapone for Parkinson’s disease
Publicado: (2023)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Absorption, metabolism and excretion of opicapone in human healthy volunteers
por: Loureiro, Ana I., et al.
Publicado: (2022)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study
por: Olanow, C. Warren, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
por: Loureiro, Ana I., et al.
Publicado: (2021)

Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson’s Disease
por: Fabbri, Margherita, et al.
Publicado: (2017)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Clinical Utility of Opicapone in the Management of Parkinson’s Disease: A Short Review on Emerging Data and Place in Therapy
por: Azevedo Kauppila, Linda, et al.
Publicado: (2021)

The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers
por: Tolosa, Eduardo, et al.
Publicado: (2021)

Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Utility of tolcapone in fluctuating Parkinson’s disease
por: Stocchi, Fabrizio, et al.
Publicado: (2006)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study
por: Stocchi, Fabrizio, et al.
Publicado: (2015)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease
por: Virmani, Tuhin, et al.
Publicado: (2016)

Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease
por: Nagayama, Hiroshi, et al.
Publicado: (2015)

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
por: Vokurka, Petr, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6kpknps05mlc9f7ug1qqdvim8n